Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (1-10 of 685) with videos related to

Pageof 69
Sort By:
Current Opinion in Obstetrics & Gynecology|May 7, 2004
Breast conservation in breast cancer: surgical and adjuvant considerationsFunda Meric-Bernstam
Annals of Surgical Oncology|April 5, 2007
Heterogenic loss of BRCA in breast cancer: the "two-hit" hypothesis takes a hitFunda Meric-Bernstam
Annals of Surgical Oncology|September 24, 2004
Serum proteomics for BRCA1-associated breast cancerFunda Meric-Bernstam
Annals of Surgical Oncology|August 21, 2008
Translation initiation factor 4E (eIF4E): prognostic marker and potential therapeutic targetFunda Meric-Bernstam
Cancer|March 8, 2011
HER2 studies look promisingFunda Meric-Bernstam
Nature Medicine|August 25, 2025
The need for molecular tumor boardsFunda Meric-Bernstam
Nature|April 15, 2026
How effective is the personalized off-label use of targeted cancer treatment?Funda Meric-Bernstam
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|March 28, 2020
Antibody-Drug Conjugates: Patient and Treatment SelectionShalini Makawita, Funda Meric-Bernstam
Expert Opinion on Investigational Drugs|October 10, 2019
Targeting AKT for cancer therapyMaryam Shariati, Funda Meric-Bernstam
Clinical Advances in Hematology & Oncology : H&O|August 27, 2019
Next-generation sequencing for the general cancer patientMonica Avila, Funda Meric-Bernstam
Pageof 69

Showing results (1-10 of 685) with videos related to

Sort By:
Pageof 69
Current Opinion in Obstetrics & Gynecology|May 7, 2004
Breast conservation in breast cancer: surgical and adjuvant considerationsFunda Meric-Bernstam
Annals of Surgical Oncology|April 5, 2007
Heterogenic loss of BRCA in breast cancer: the "two-hit" hypothesis takes a hitFunda Meric-Bernstam
Annals of Surgical Oncology|September 24, 2004
Serum proteomics for BRCA1-associated breast cancerFunda Meric-Bernstam
Annals of Surgical Oncology|August 21, 2008
Translation initiation factor 4E (eIF4E): prognostic marker and potential therapeutic targetFunda Meric-Bernstam
Cancer|March 8, 2011
HER2 studies look promisingFunda Meric-Bernstam
Nature Medicine|August 25, 2025
The need for molecular tumor boardsFunda Meric-Bernstam
Nature|April 15, 2026
How effective is the personalized off-label use of targeted cancer treatment?Funda Meric-Bernstam
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|March 28, 2020
Antibody-Drug Conjugates: Patient and Treatment SelectionShalini Makawita, Funda Meric-Bernstam
Expert Opinion on Investigational Drugs|October 10, 2019
Targeting AKT for cancer therapyMaryam Shariati, Funda Meric-Bernstam
Clinical Advances in Hematology & Oncology : H&O|August 27, 2019
Next-generation sequencing for the general cancer patientMonica Avila, Funda Meric-Bernstam
Pageof 69